Safety & Tolerability

EPS and akathisia profile was similar to placebo with CAPLYTA1,3

Incidence of extrapyramidal symptoms (EPS)* and akathisia in acute trials (4- to 6-week)1,3

Incidence of extrapyramidal symptoms (EPS)* and akathisia in acute trials
  • Data were collected in patients with acute schizophrenia over 4-6 weeks1,3

EPS (extrapyramidal symptoms) includes akathisia, extrapyramidal disorder, muscle spasms, restlessness, musculoskeletal stiffness, dyskinesia, dystonia, muscle twitching, tardive dyskinesia, tremor, drooling, and involuntary muscle contractions.1